Caregivers and Electronic Medication Monitoring in Chronic Kidney Disease

NCT ID: NCT01087255

Last Updated: 2011-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this pilot study is to explore barriers to medication adherence among HPHC members with CKD, particularly those not yet on dialysis, and to assess the feasibility and acceptability of a wireless, internet-based MedMinder system intervention among HPHC enrollees with CKD and their care partners. The investigators hypothesize that the intervention will improve medication use and adherence among patient members with CKD on complex medication treatment, and improve informal caregivers' ability to provide support for improved medication use among patient members.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adherence to medications is critical in managing chronic disease, yet it remains an issue across chronic conditions. Poor medication adherence leads to deteriorating health and subsequently to increased costs as a result of higher hospitalizations rates. Medication adherence in chronic kidney disease (CKD) is especially important because successful treatment can slow the progression to end-stage renal disease (ESRD), yet little research has focused on adherence in patients with early CKD. Numerous barriers to medication adherence exist, including the prescription of complex medication regimens, the often asymptomatic nature of early CKD, and the lack of social support for treatment adherence. While technology and support-based interventions show promise, there currently is no gold-standard approach to improving medication adherence. Thus, it is essential to pursue novel interventions that address barriers for patients with CKD to improve medication adherence and slow the progression to ESRD.

The long-range goal of this application is to improve medication adherence in chronic illness through the development of effective interventions that capitalize on patients' medication-taking context. The objective of this application, which is the next step to achieving that goal, is to pilot test the impact and acceptability of the MedMinder, a pillbox device that transmits medication-taking data via a secure internet-interface to patients, family members, and care managers, in a group of adult, Harvard Pilgrim Health Care (HPHC) members with CKD. To achieve this objective, in partnership with HPHC, we will recruit 120 members with diagnosed CKD stage III or IV to participate in a 6-month pre-post randomized-controlled trial. Participants will be randomized to either receive use of the MedMinder over a six-month period with access to telephone care management, or receive usual care of regular pillboxes with access to telephone care management.

Our primary aim is to test the feasibility and acceptability of the MedMinder intervention. The main components of the intervention include: (1) a plastic weekly pill box with programmable visual and auditory cues to prompt medication use, (2) generation of missed-dose alerts that can be sent via email, text message, or telephone to patients, family members, and HPHC care managers, (3) a secure internet site that permits customization of alerts and has graphical representations of medication use, and (4) aggregate adherence reports available to CKD care managers for patients who are participating in HPHC care management.

Our secondary aim is to assess the impact and acceptability of family and friend involvement in CKD member medication taking. We will document family and friend activities related to medication taking, the acceptability of family and friend involvement in member medication taking, and the impact such involvement has on medication use.

Findings of this proposed project would provide information on the feasibility of a technology-based adherence intervention, with medication-taking support, in patients with chronic disease. The results from this pilot will inform a future application for a more adequately powered study examining the intervention and measurement of structured support from others in medication taking.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease Medication Adherence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care

Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.

Group Type NO_INTERVENTION

No interventions assigned to this group

Electronic Pillbox Monitoring System

Usual care plus receive use of the wireless electronic pillbox and medication monitoring system

Group Type EXPERIMENTAL

Electronic Pillbox Monitoring System

Intervention Type DEVICE

Daily exposure for six months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electronic Pillbox Monitoring System

Daily exposure for six months

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MedMinder

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HPHC commercial- or Medicare-insured members with 2 or more distinct outpatient nephrology chronic kidney disease stage (CKD) III, IV, or V diagnoses in a 6-month period.
* 18 years old or older at the time they are identified as having CKD.
* An average of two prescription medications dispensed per month in the prior 6-months.
* Residence in MA, ME, or NH
* Residence in an area with MedMinder-participating cellular coverage (includes most major cellular carriers)

Exclusion Criteria

* Dialysis or dialysis-related complication medical service claims in 6-month period preceding study entry.
* Atrius Health member
* Serious mental illness or cognitive dysfunction medical service claim in 6-month period preceding study entry
* Primary language other than English
* Unable to use a pillbox
* Have no eligible caregiver
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Harvard Pilgrim Health Care

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Population Medicine, Harvard Pilgrim Health Care Institute

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Connie M Trinacty, PhD

Role: PRINCIPAL_INVESTIGATOR

Harvard Medical School and Harvard Pilgrim Health Care Institute

Ashley J Beard, PhD

Role: STUDY_DIRECTOR

University of Michigan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Harvard Pilgrim Health Care

Wellesley, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Connie M Trinacty, PhD

Role: CONTACT

617-509-9955

Ashley J Beard, PhD

Role: CONTACT

734-845-3813

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Carla Rosenkras, RN, MPH

Role: primary

617-509-7565

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PF000123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Patient-driven Management of BP in CKD
NCT05546099 RECRUITING PHASE3
The eDosette Pilot Study
NCT03513224 COMPLETED NA
APHID- Primary Care Accuracy Study
NCT02135731 COMPLETED NA